摘要
The 2023 update of the Chinese Society of Clinical Oncology(CSCO)Clini-cal Guidelines for Gastric Cancer focuses on standardizing cancer diagnosis and treatment in China,reflecting the latest advancements in evidence-based medicine,healthcare resource availability,and precision medicine.These updates address the differences in epidemiological characteristics,clinicopatho-logical features,tumor biology,treatment patterns,and drug selections between Eastern and Western gastric cancer patients.Key revisions include a structured template for imaging diagnosis reports,updated standards for molecular marker testing in pathological diagnosis,and an elevated recommendation for neoadju-vant chemotherapy in stage III gastric cancer.For advanced metastatic gastric cancer,the guidelines introduce new recommendations for immunotherapy,anti-angiogenic therapy and targeted drugs,along with updated management strategies for human epidermal growth factor receptor 2(HER2)-positive and deficient DNA mismatch repair(dMMR)/microsatellite instability-high(MSI-H)patients.Additionally,the guidelines offer detailed screening recommendations for hereditary gastric cancer and an appendix listing drug treatment regimens for various stages of gastric cancer.The 2023 CSCO Clinical Guidelines for Gastric Cancer updates are based on both Chinese and international clinical research and expert consensus to enhance their applicability and relevance in clinical practice,particularly in the heterogeneous healthcare landscape of China,while maintaining a commitment to scientific rigor,impartiality,and timely revisions.
作者简介
Rui-Hua Xu,Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center of Cancer Medicine,Guangzhou 510060,Guangdong,P.R.China.Email:xurh@sysucc.org.cn,https://orcid.org/0000-0001-9771-8534;Jin Li,Department of Oncology,Easter Hospital affiliated to Shanghai Tongji University,Shanghai 200120,P.R.China.Email:lijin@csco.org.cn;Lin Shen,Department of GI Oncology,Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education),Peking University Cancer Hospital.Beijing 100142,P.R.China.Email:shenlin@bjmu.edu.cn,Lin Shen,https://orcid.org/0000-0002-8798-4756;Feng-Hua Wang,https://orcid.org/0000-0003-1016-6867;Mu-Yan Cai,https://orcid.org/0000-0002-4646-4391;Yuan-Fang Li,https://orcid.org/0000-0003-1762-2634;Jie-Er Ying,https://orcid.org/0000-0001-9452-1242;Jun Zhang,https://orcid.org/0000-0002-7973-8416;Rong-Bo Lin,https://orcid.org/0000-0002-6877-1691;Chang Wang,https://orcid.org/0000-0003-1435-0143,Miao-Zhen Qiu,https://orcid.org/0000-0002-4774-6235,Hui-Mian Xu,https://orcid.org/0000-0002-1177-4445;Feng Bi,https://orcid.org/0000-0002-0527-5105;Han Liang,https://orcid.org/0000-0002-5674-0994。
